CGAS and autoimmune disease: A variety of small molecules able to inhibit cGAS activation have been successfully identified and developed in treating autoimmune diseases, such as RU.521, which competitively binds to cGAS catalytic pocket with cGAS substrates ATP/GTP [40], Cu-32 and Cu-76, that prevent cGAS dimerisation and subsequence activation [41], and additional small molecules identified through screenings: G140/G150 [42] and PF-06928215 [43].